The Use of Valrubicin for the Chemoresection of Superficial Bladder Cancer – A Marker Lesion Study

Objectives: To assess the effect and tolerance of a 6–week course of intravesical valrubicin on a tumour intentionally left in the bladder (marker lesion) following incomplete transurethral resection of the bladder (TURBT). Patients and Methods: In a prospective phase II study, 40 patients with refr...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European urology 2001-06, Vol.39 (6), p.643-647
Hauptverfasser:	Newling, D.W.W., Hetherington, J., Sundaram, S.K., Robinson, M.R.G., Kisbenedek, L.
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Intravesical Aged Biological and medical sciences Bladder and Urothelial Cancer Carcinoma, Transitional Cell - drug therapy Carcinoma, Transitional Cell - pathology Carcinoma, Transitional Cell - surgery Doxorubicin - administration & dosage Doxorubicin - analogs & derivatives Doxorubicin - therapeutic use Female Humans Male Medical sciences Middle Aged Neoplasm Recurrence, Local - drug therapy Neoplasm Recurrence, Local - pathology Neoplasm Recurrence, Local - surgery Nephrology. Urinary tract diseases Prospective Studies Time Factors Tumors of the urinary system Urinary Bladder - drug effects Urinary Bladder - pathology Urinary Bladder - surgery Urinary Bladder Neoplasms - drug therapy Urinary Bladder Neoplasms - pathology Urinary Bladder Neoplasms - surgery Urinary tract. Prostate gland
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Objectives: To assess the effect and tolerance of a 6–week course of intravesical valrubicin on a tumour intentionally left in the bladder (marker lesion) following incomplete transurethral resection of the bladder (TURBT). Patients and Methods: In a prospective phase II study, 40 patients with refractory superficial transitional cell carcinoma (TCC), with or without carcinoma in situ, underwent TURBT at which a tumour
ISSN:	0302-2838 1873-7560 1421-993X
DOI:	10.1159/000052521